Insulin (Long-Acting)
Lantus · Glargine · Detemir
Long-acting insulin analogues (glargine/Lantus, detemir/Levemir) are prescription basal insulins engineered for slow, relatively peakless glucose lowering over ~24 hours in diabetes. In the physique/PED community they are misused off-label as a purported "anabolic" to drive nutrient uptake into muscle, but there is no human efficacy evidence that they build muscle in non-diabetic people. Insulin is one of the most lethal drugs of misuse. In a non-diabetic person even modest doses can cause profound, prolonged hypoglycemia leading to seizures, permanent brain injury, coma, and death, and documented bodybuilder cases have required intensive-care glucose/glucagon rescue and mechanical ventilation. Because these are long-acting formulations, an overdose is not a brief event: glucose must often be supplemented for many hours and hypoglycemia can recur long after the injection. It also drives potassium into cells (dangerous hypokalemia), causes weight gain, and injection sites can develop fat lumps/atrophy. There is no safe self-directed way to use insulin as a performance drug; this monograph is risk-forward and defers all decisions to a physician/endocrinologist.
Mechanism of action
Pharmacokinetics
Prolonged and formulation-dependent. In euglycemic-clamp human studies the measured duration of action (a more meaningful metric than plasma half-life for these depot formulations) at steady state was ~27 h for glargine U-100 and ~23 h for detemir, with wide inter-individual ranges (glargine 10.5-29 h; detemir 4-30 h). Newer ultra-long agents (glargine U-300, degludec) have even longer half-lives (~24 h+) and durations >24 h.
Approximately 24 hours for glargine U-100 and detemir at typical doses, but detemir is notably dose-dependent (shorter at low doses) and both show large person-to-person variability. Clinically relevant point for overdose: glucose-lowering effect can persist and hypoglycemia can recur for many hours; in high-dose insulin toxicity, glucose supplementation is often required for up to ~24 h after the insulin is stopped.
Subcutaneous injection only. Long-acting analogues must never be given intravenously (glargine's action depends on subcutaneous microcrystal precipitation; IV use produces rapid, catastrophic hypoglycemia).
Cleared by receptor-mediated internalization/degradation in liver, kidney, and peripheral tissue; insulin-degrading enzyme is the principal catabolic pathway. Renal and hepatic impairment reduce clearance and prolong action. Framed here for washout/monitoring after overdose, not for any timing or evasion purpose.
For monitoring and washout planning, not drug-test evasion.
Physiological & performance effects
- Lowers blood glucose by increasing peripheral glucose uptake and suppressing hepatic glucose output (the intended pharmacologic effect in diabetes)
- Promotes protein synthesis and inhibits protein breakdown, and stimulates glycogen storage and lipogenesis (the mechanistic basis cited for misuse)
- Causes weight gain: in the ORIGIN randomized trial median weight rose ~1.6 kg with glargine versus a 0.5 kg fall with standard care
- Shifts potassium intracellularly, lowering serum potassium
- No human evidence of muscle-building, fat-loss, or performance benefit in non-diabetic people; purported ergogenic effects are unproven
Adverse effects by system
Long-term basal glargine had a neutral effect on major cardiovascular events in the large ORIGIN RCT (>12,000 dysglycemic subjects, ~6 yr). However, the acute hypoglycemia that insulin misuse causes is itself linked to cardiac arrhythmias, QT prolongation, and sudden death, and severe hypoglycemia is associated with increased cardiovascular events and mortality.
Not hepatotoxic. Insulin is not associated with drug-induced liver injury; the liver is a target organ (suppressed gluconeogenesis), not a site of toxic damage. Hepatic impairment prolongs insulin action and raises hypoglycemia risk.
Insulin does not suppress the hypothalamic-pituitary-gonadal axis or endogenous testosterone in the way androgens do; it is not androgenic. It does suppress endogenous pancreatic insulin/C-peptide secretion (the basis for diagnosing surreptitious use: high insulin with inappropriately low C-peptide). Recurrent severe hypoglycemia can blunt counter-regulatory hormone responses (hypoglycemia unawareness).
No adequate human data specifically linking exogenous long-acting insulin to fertility or reproductive harm in this misuse context; not established as a direct reproductive toxin. This is an evidence gap.
No primary psychiatric toxicity from the molecule, but neuroglycopenia from hypoglycemia produces confusion, agitation, altered consciousness, bizarre behavior, seizures, and coma. Surreptitious/factitious insulin use is itself associated with psychiatric/factitious-disorder contexts.
Not directly nephrotoxic. Renal impairment reduces insulin clearance and markedly prolongs/potentiates hypoglycemia; the kidney is a key clearance organ, so impaired function is a major risk amplifier rather than a target of injury.
No direct hematologic toxicity, but insulin drives a clinically important electrolyte effect, hypokalemia from intracellular potassium shift, which can cause weakness and cardiac arrhythmia, especially in overdose.
Injection-site lipohypertrophy (fatty lumps) and, less commonly, lipoatrophy are well described with repeated subcutaneous insulin; injecting into lipohypertrophic tissue causes erratic absorption and unpredictable hypoglycemia. Bruising and local injection-site reactions also occur.
HPTA suppression & recovery
Suppression: Not an HPTA/androgenic suppressant. Insulin does not suppress the hypothalamic-pituitary-gonadal axis; SERM-based recovery protocols are neither relevant nor applicable to insulin.
There is no post-cycle/HPTA recovery concept for insulin because it does not suppress the gonadal axis. It does suppress endogenous insulin/C-peptide secretion, and repeated hypoglycemia can impair counter-regulatory hormone responses; both are endocrine issues to be evaluated and managed by an endocrinologist, not with any SERM. Any endocrine concern must be referred to a physician/endocrinologist; do not attempt self-directed hormonal 'recovery.'
Monitoring
Cadence: In any suspected overdose, glucose must be monitored continuously/serially and supplementation continued for up to ~24 h after a long-acting insulin because effect outlasts a single glucose correction. Any non-prescribed use warrants prompt medical evaluation rather than a fixed self-monitoring schedule.
- Sweating, tremor, palpitations, intense hunger, anxiety (early adrenergic hypoglycemia)
- Confusion, slurred speech, blurred vision, bizarre behavior, drowsiness (neuroglycopenia)
- Seizures, loss of consciousness, coma—call emergency services immediately
- Muscle weakness, cramps, or palpitations suggesting hypokalemia
- Recurrent hypoglycemia hours after a dose (hallmark of long-acting insulin)
Contraindications
- Non-diabetic use for physique/performance purposes—there is no medical indication and the hypoglycemia risk is potentially fatal
- Any current or pre-existing hypoglycemia or hypoglycemia unawareness
- Use without immediate access to fast-acting carbohydrate, glucose, and ideally glucagon and a person who can summon emergency help
- Renal or hepatic impairment (markedly prolonged, unpredictable action)
- Intravenous administration of long-acting analogues
- Injection into lipohypertrophic sites or unfamiliar dosing/units (U-100 vs U-300/U-500 confusion causes lethal dosing errors)
- Concurrent alcohol, prolonged fasting, or heavy exercise, all of which deepen and prolong hypoglycemia
- Combining with other glucose-lowering agents
Interaction profile
- MajorWith growth hormone: Metabolic / glucose
- MajorWith IGF-1: Metabolic / glucose
- MajorWith a GLP-1 / incretin agonist: Metabolic / glucose
- MajorWith another insulin: Metabolic / glucose
- MajorWith a β2-agonist: Metabolic / glucose
- ContraindicatedWith DNP: Additive cardiovascular strain
Check a specific combination in the interaction checker.
Reducing harm & when to stop
- Insulin misuse can kill; there is no established safe non-medical dose and no human evidence it improves physique or performance in non-diabetic people.
- Hypoglycemia from a long-acting insulin is prolonged and can recur for many hours—a single sugary drink does not 'fix' it. Treat and then keep eating carbohydrate and monitoring glucose for many hours.
- Recognize hypoglycemia early: sweating, shakiness, hunger, palpitations, anxiety, then confusion/slurred speech; take fast carbohydrate immediately.
- Any seizure, unconsciousness, or hypoglycemia that does not rapidly and durably respond to carbohydrate is a medical emergency—call emergency services; injectable glucagon can be life-saving while awaiting help.
- Never inject a long-acting analogue intravenously and never confuse concentrations (U-100 vs U-300/U-500)—dosing errors are a common cause of severe harm.
- Do not use around alcohol, fasting, or heavy exercise, which deepen hypoglycemia; do not use alone.
- Watch for and report symptoms of low potassium (weakness, cramps, palpitations).
- If you have used non-prescribed insulin, seek medical care; unexplained hypoglycemia is worked up with paired insulin and C-peptide, and honest disclosure guides safe treatment.
- All decisions about insulin belong with a physician/endocrinologist; this content is not a protocol for use.
Citations (12)
Every clinical claim above is tied to a primary source. Overall evidence grade B — graded to the best available evidence for its core claims.
- 01
Long-acting basal insulins (glargine, detemir) are engineered for a flatter, protracted ~24 h time-action profile via isoelectric-point shift (glargine) and fatty-acid/albumin binding (detemir); detemir shows a mild hepatoselective effect and both reduce hypoglycemia vs conventional insulin in diabetics.
ReviewPMID 19120431 ↗
- 02
In human euglycemic-clamp studies in type 1 diabetes, steady-state duration of action was ~27 h for glargine and ~23 h for detemir, with wide individual ranges.
- 03
Next-generation long-acting insulins (glargine U-300, degludec) have longer half-lives and durations of action with more even 24 h distribution and lower nocturnal hypoglycemia rates; long-term cardiovascular safety not fully established.
ReviewPMID 28077204 ↗
- 04
Insulin misused as an anabolic by a bodybuilder caused severe hypoglycemia with loss of consciousness and convulsions requiring IV glucose and glucagon rescue.
Case reportDOI 10.1055/s-2007-994284 ↗
- 05
A bodybuilder presented in coma from severe, treatment-refractory hypoglycemia due to cryptic (surreptitious) exogenous insulin used as an ergogenic aid, requiring iterative glucose infusions.
Case reportDOI 10.1016/j.jemermed.2018.10.030 ↗
- 06
In the ORIGIN RCT, basal glargine had a neutral effect on cardiovascular outcomes and cancer over ~6 years, but increased severe hypoglycemia (1.00 vs 0.31 per 100 person-years) and modestly increased weight (+1.6 kg vs -0.5 kg).
- 07
Severe hypoglycemia is associated with increased cardiovascular events and mortality and can induce cardiac arrhythmias, with a reported case of sudden death during a severe episode.
- 08
Insulin glargine has significantly increased affinity for the IGF-1 receptor and greater in-vitro mitogenic potency in some cancer cell lines, raising theoretical (unconfirmed) mitogenicity concerns.
ReviewPMID 19224503 ↗
- 09
The carcinogenic risk of long-acting analogues, and specifically glargine, can be neither confirmed nor excluded; the only prospective trial found no cancer increase and clinical evidence is contrasting.
- 10
Repeated subcutaneous insulin injection causes lipohypertrophy and lipoatrophy at injection sites.
- 11
Surreptitious exogenous insulin use is diagnosed by elevated insulin with inappropriately low C-peptide, distinguishing it from endogenous hyperinsulinism.
Case reportDOI 10.7759/cureus.5872 ↗
- 12
Insulin shifts potassium from extracellular to intracellular space, causing hypokalemia; in high-dose insulin exposure the anticipated adverse effects are hypoglycemia and hypokalemia, and glucose supplementation is required for up to ~24 h after stopping insulin.
Last reviewed 2026-07-06 · Verified against PubMed · Educational, not medical advice